IL13RA2 and neoplasm: In addition, targeting YKL-40 receptor IL-13Rα2 is also anticipated to serve as a potent alternative strategy for either blocking YKL-40-induced tumor vascularization or eliciting a synergetic effect in conjunction with mAY.